EZH2 Inhibition as New Epigenetic Treatment Option for Pancreatic Neuroendocrine Neoplasms (PanNENs)

EZH2 Inhibition as New Epigenetic Treatment Option for Pancreatic Neuroendocrine Neoplasms (PanNENs)

Pancreatic neuroendocrine neoplasms are epigenetically driven tumors, but therapies against underlying epigenetic drivers are currently not available in the clinical practice. We aimed to investigate EZH2 (Enhancer of Zest homolog) expression in PanNEN and the impact of EZH2 inhibition in three diff...

Full description

Bibliographic Details
Main Authors: Simon Leonhard April-Monn, Valentina Andreasi, Marco Schiavo Lena, Martin Carl Sadowski, Corina Kim-Fuchs, Michelle Claudine Buri, Avanee Ketkar, Renaud Maire, Annunziata Di Domenico, Jörg Schrader, Francesca Muffatti, Claudio Doglioni, Stefano Partelli, Massimo Falconi, Aurel Perren, Ilaria Marinoni
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Cancers
Subjects:
pancreatic neuroendocrine neoplasms
EZH2 (Enhancer of Zest homolog)
tumor treatment
epigenetic treatment
histone modification
Online Access:https://www.mdpi.com/2072-6694/13/19/5014

Internet

https://www.mdpi.com/2072-6694/13/19/5014

Similar Items